These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MRI for the assessment of malignancy in BI-RADS 4 mammographic microcalcifications.
    Author: Bennani-Baiti B, Dietzel M, Baltzer PA.
    Journal: PLoS One; 2017; 12(11):e0188679. PubMed ID: 29190656.
    Abstract:
    PURPOSE: Assess the performance of breast MRI to diagnose breast cancer in BI-RADS 4 microcalcifications detected by mammography. MATERIALS AND METHODS: This retrospective, IRB-approved study included 248 consecutive contrast-enhanced breast MRI (1.5T, protocol in accordance with EUSOBI recommendations) performed to further diagnose BI-RADS 4 microcalcifications detected at mammography during a 3-year period. Standard of reference had to be established by histopathology. Routine consensus reading results by two radiologists were dichotomized as positive or negative and compared with the reference standard (benign vs malignant) to calculate diagnostic parameters. RESULTS: There were 107 malignant and 141 benign microcalcifications. Malignancy rates were 18.3% (23/126 BI-RADS 4a), 41.7% (25/60 BI-RADS 4b) and 95% (59/62 BI-RADS 4c). There were 103 true-positive, 116 true-negative, 25 false-positive, and 4 false-negative (one invasive cancer, three DCIS; 2 BI-RADS 4c, 1 BI-RADS 4b on mammography) breast MRI findings, effecting a sensitivity, specificity, PPV, and NPV of 96.3% (95%-CI 90.7-99.0%), 82.3% (95%-CI 75.0-88.2%), 80.5% (95%-CI 72.5-87.0%) and 96.7% (95%-CI 91.7-99.1%), respectively. CONCLUSION: MRI is an accurate tool to further diagnose BI-RADS 4a and 4b microcalcifications and may be helpful to avoid unnecessary biopsies in BI-RADS 4a and 4b lesions. BI-RADS 4c microcalcifications should be biopsied irrespective of MRI findings.
    [Abstract] [Full Text] [Related] [New Search]